氨酸剂量和药物基因组学:基于UGT1A1变体和新兴见解的全面探索
Muhammad Saleem Faisal1, Imran Hussain1, Muhammad Abdullah Ikram2
1Department of Biological Sciences, International Islamic University, Islamabad, Pakistan.
Journal of chemotherapy (Florence, Italy)
|May 6, 2024
概括
对UGT1A1变异的遗传查可以个性化化疗. 这种方法有助于减少癌症患者中性质衰竭和腹等严重的副作用.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 伊利诺特坎是转移性结肠直肠癌和胰腺癌的重要化疗剂,其向毒酶1.
- 包括中性质减肥和腹在内的不良反应是与氨酸治疗相关的重大挑战.
- 在UDP葡萄糖转移酶家族1成员A1 (UGT1A1) 中的多态性与增加的虹素毒性有关.
研究的目的:
- 审查UGT1A1基因型导向的阴素剂量对治疗结果的影响.
- 探索策略,以尽量减少色素诱导的癌症患者的毒性.
- 评估UGT1A1基因测试在临床实践中的成本效益.
主要方法:
- 对UGT1A1变种 (*28和 *6) 和 irinotcan的药物基因组学研究的综合综述.
- 对结直肠癌和胰腺癌的既定和新兴义诺太干疗法进行分析.
- 检查临床指导方针,以管理与氨酸相关的毒性.
- 关于UGT1A1基因型测试的经济数据的评估.
主要成果:
- UGT1A1基因型测试可以为个性化虹素剂量提供信息,以减轻毒性.
- 特定的UGT1A1变异 (*28, *6) 与较高的不良事件风险有关.
- 脂质体配方可能为胰腺癌中虹色素的输送提供了更好的安全性.
- 证据支持基因型导向剂量的临床实用性,以优化虹素治疗.
结论:
- 根据UGT1A1基因型指导的剂量是提高虹素素安全性和疗效的有价值的策略.
- 建议在治疗前对UGT1A1多态基因进行基因查,以个性化化疗.
- 对成本效益和实施策略的进一步研究是有必要的.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
7.9K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:24Phase II Reactions: Glucuronidation
396
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
396
01:27Nonlinear Pharmacokinetics: Role of Transporters
48
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
48
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K